北京若生智能科技有限公司
Drug Database
SA

salbutamol (Inspiryl Turbuhaler)

✓ Approved

AstraZeneca UK Limited · ADRB2 · 小分子

什么是 salbutamol？

salbutamol 是一种小分子，由AstraZeneca UK Limited研发。该药已获批，用于治疗相关适应症，给药途径：Inhaled、Topical。

药物档案

商品名Inspiryl Turbuhaler
公司AstraZeneca UK Limited
药物类别小分子
分子靶点ADRB2
给药途径Inhaled, Topical
状态Approved
来源： ClinicalTrials.gov, AstraZeneca UK Limited

作用机制

分子靶点

salbutamol 作用于 1 个分子靶点：

ADRB2adrenoceptor beta 2 (B2AR, ARB2)
需要更深入的分析？Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

salbutamol 针对 1 个适应症，涉及 1 个治疗领域。

治疗领域疾病/病症分期
Respiratory, thoracic and mediastinal disordersAsthma✓ Approved

相关研究文献

PubMedERJ open research2026-09-08

A study protocol for a randomised controlled trial of two stepwise pharmacological treatment approaches to adult asthma: inhaled corticosteroid/formoterol reliever- versus short-acting β2-agonist reliever-based therapy - Asthma on TRACK.

Sayers Ross R, Cullen Ryan R, Oldfield Karen K, Barrett Jonathan J et al.

No randomised controlled trials (RCTs) have compared inhaled corticosteroid (ICS)/formoterol reliever-based stepwise algorithms with short-acting β-agonist (SABA) reliever-based stepwise algorithms, titrated to levels of asthma control and exacerbations. Knowledge gaps remain in understanding ICS exposure over time, transitions between treatment steps, efficacy and participant satisfaction with different algorithm approaches. The aim of the study is to determine the exposure to ICS in adults and adolescents aged 16 to 75 years treated with a budesonide/formoterol reliever-based algorithm (Algorithm 1) compared to a salbutamol reliever-based algorithm (Algorithm 2) across the spectrum of asthma severity. This is an investigator-initiated, 52-week, single-site, open-label, parallel-groups, 2-arm RCT of 152 adults and adolescents with mild, moderate and moderate-severe asthma (ACTRN12624001488594). Participants will be randomly allocated in a 1:1 ratio to a budesonide/formoterol reliever-based or a salbutamol reliever-based algorithm. Global Initiative for Asthma (GINA) treatment step at enrolment according to the 2024 GINA Guidelines will be used to allocate participants to the corresponding steps of each algorithm. Treatment step transition will be in response to asthma exacerbations and level of asthma control. Those experiencing exacerbations or poorly controlled asthma will be stepped up, and those well controlled stepped down. The primary outcome is ICS exposure. Important secondary outcomes include composite systemic corticosteroid exposure, rates of asthma exacerbations, asthma control, T-helper 2 biomarkers, spirometry and participants' treatment perceptions and satisfaction. This is the first RCT to compare ICS/formoterol- and SABA-based reliever stepwise algorithmic approaches in asthma, with treatment adjusted according to asthma control and exacerbations.

PMID 42707905
阅读全文 →
PubMedDrug development and industrial pharmacy2026-08-30

Development of extended-release oral dosage forms of salbutamol sulfate using the Hot-Melt extrusion manufacturing technique.

Ramadan Banan B, Al-Zoubi Nizar N, Migdadi Eman E, AlSuwais Alia Kh AK et al.

To fabricate and characterize extrudable polymeric matrices using a combination of ethyl cellulose (EC) and two different grades of hydroxypropyl cellulose (HPC) that can provide sustained drug release of the model drug salbutamol sulfate. Implementation of the Hot-Melt Extrusion (HME) technique in the fabrication of polymeric combinations that will provide ready-to-use matrices for sustained release dosage forms. Two formulation groups were developed; each with six formulations. The first group contained EC: HPC 370,000 ratios ranging from 55.52:13.8% to 6.9:62.46%, respectively. The second group contained EC: HPC 80,000 ranging from 59.4:10% to 9.4:60%, respectively. The release profiles were determined via in vitro studies to assess the ability of matrices to prolong salbutamol release. Solid-state characterization was also performed on the raw material and representative extrudates formulations using differential scanning calorimetry (DSC) and X-ray powder diffraction (XRPD) and polarized light microscopy (PLM). The first group formulations exhibited prolonged drug release profiles that accelerated progressively as the level of HPC 370,000 increased. In contrast, the second group formulations exhibited a noticeably faster release, demonstrating that HPC 80,000 can effectively accelerate drug release through enhanced matrix erosion and water penetration. DSC and XRPD revealed that the model drug remained in its stable crystalline state even after thermal processing via HME. PLM further confirmed drug crystallinity within the extrudates. EC-HPC matrices successfully demonstrated the feasibility of using HME to prepare sustained-release matrices for salbutamol sulfate with the ability to tune drug release by varying polymer grade and ratio.

PMID 42669207
阅读全文 →
PubMedJournal of clinical medicine2026-08-27

Discordance Between Clinical Suspicion and Spirometry-Defined Reversible Airflow Obstruction in Children with Sickle Cell Disease in French Guiana.

Bafunyembaka Gabriel G, Evens Estiverne E, Nathan Nadia N, Makembi Arriel A et al.

Background: Asthma is an important respiratory comorbidity in children with sickle cell disease (SCD), but respiratory symptoms overlap with SCD-related pulmonary manifestations. Methods: We analyzed prospectively recorded routine-care data from 140 children aged 5-17 years who were offered a standardized respiratory assessment during clinically stable follow-up. During revision, we applied a post hoc operational spirometric comparator: reversible airflow obstruction required FEV1/FVC < 80% plus an FEV1 increase ≥12% after salbutamol. Participants with normal spirometry formed the negative comparator; incomplete or intermediate objective patterns remained unclassified. Results: Reversible obstruction was identified in 43 children, normal spirometry in 25, and 72 remained unclassified. Previous clinical suspicion was present in 10/43 (23.3%), 3/25 (12.0%), and 22/72 (30.6%), respectively. In the deliberately contrastive classified-only analysis (n = 68), sensitivity was 23.3% (95% CI 11.8-38.6), specificity 88.0% (68.8-97.5), LR+ 1.94 (0.59-6.39), LR- 0.87 (0.70-1.09), and κ = 0.090 (95% CI -0.059 to 0.239). The likelihood-ratio intervals were wide and included 1.0, indicating substantial imprecision rather than proof of no discrimination. Conclusions: Prior clinical suspicion showed low sensitivity and slight agreement with spirometry-defined reversible obstruction. Interpretation is limited by the post hoc two-gate comparison and by the large, non-randomly distributed unclassified group.

PMID 42652746
阅读全文 →
PubMedCanadian journal of anaesthesia = Journal canadien d'anesthesie2026-08-26

Effect of salbutamol during one-lung ventilation in patients with chronic obstructive pulmonary disease: a randomized controlled trial.

Oh Young Jun YJ, Kim Namo N, Choo Hyeonju H, Lee Kyuho K

Ventilation-perfusion mismatch during one-lung ventilation (OLV) for thoracic surgery increases the risk of hypoxemia. Salbutamol may selectively dilate pulmonary vessels and enhance perfusion of the ventilated lung. We sought to investigate whether selective salbutamol nebulization to the ventilated lung during OLV improves gas exchange and respiratory mechanics in patients with chronic obstructive pulmonary disease (COPD). In this prospective randomized controlled trial, we randomly allocated 90 patients scheduled for lung resection to receive salbutamol or placebo nebulization 30 min after OLV initiation and analyzed 82 patients (41 per group). The primary endpoint was the change in the partial pressure of arterial oxygen/fraction of inspired oxygen (PaO2/FIO2) after nebulization. Secondary outcomes included other gas exchange and respiratory mechanics indices, hemodynamic variables, and perioperative complications. Compared with placebo, salbutamol increased PaO2/FIO2 (mean difference, 26; 95% confidence interval [CI], 0 to 53; P = 0.03) and decreased alveolar dead space (mean difference, -1.7; 95% CI, -4.3 to -0.1; P = 0.04) as well as serum potassium (mean difference, -0.2; 95% CI, -0.4 to 0.0; P = 0.01). Heart rate rose transiently without arrhythmia. In a subgroup of patients who had received preoperative inhaler therapy, no between-group differences were observed. Selective salbutamol nebulization during OLV improved oxygenation and respiratory mechanics without serious adverse events, and it may be considered as an adjunctive option for the management of intraoperative hypoxemia in patients with COPD. The lack of benefit among patients who received preoperative inhaler therapy suggests that intraoperative selective one-lung nebulization may be more advantageous than preoperative two-lung nebulization. ClinicalTrials.gov ( NCT05914285 ); first submitted 13 June 2023.

PMID 42645752
阅读全文 →
PubMedPediatric pulmonology2026-08-24

Viral Induced Hypersecretion of Mucous (VIper): Proposal for a Distinct Phenotype of Viral Induced Lower Respiratory Tract Infection in Children.

Massie John J, Baenziger Olivia O

Some children with an acute viral lower respiratory tract illness present with a phenotype that overlaps with, but is distinct from, that of asthma. These children have shortness of breath with increased work of breathing, wet cough, hypoxia out of proportion to the work of breathing, incomplete resolution of hypoxia with supplemental oxygen, worsening of oxygen saturation after salbutamol and improvement of oxygen saturation with coughing. The pathophysiology appears to relate to relate to excess mucous secretion in the airways causing ventilation:perfusion (V/Q) mismatching, which is then exacerbated by salbutamol use. A descriptive label for this condition is Viral Induced hypersecretion of mucous (VIper). Since this has yet to receive formal recognition as a subtype of viral induced lower respiratory tract infection in children, there are no published therapeutic trials of management. This letter details the proposed pathophysiological mechanisms of mucous hypersecretion and V?Q mismatching. The value of considering VIper as a distinct subset of viral lower respiratory tract infection is to prevent harmful treatments and offer the opportunity for prospective trials of effective therapies.

PMID 42634888
阅读全文 →
PubMedFrontiers in pediatrics2026-08-15

Body mass index, lung function, and FeNO in children with positive bronchodilator response: a cross-sectional study.

Zhou Tingting T, Liu Juan J, Lin Yuanyuan Y, Zhang Guilan G et al.

To investigate the association between body mass index (BMI) and pulmonary function in pediatric outpatients with positive bronchodilator response. We hypothesized that BMI is associated with impaired pulmonary function in this population. This cross-sectional study was conducted at the Department of Pediatrics of Mianyang Central Hospital from January 2024 to December 2024. A total of 430 children aged 4-14 years who met the inclusion criteria were enrolled. Based on body mass index (BMI), participants were categorized into an higher BMI group (n = 78), a normal BMI group (n = 338), and an lower BMI group (n = 14). Pulmonary function tests were performed to measure forced vital capacity (FVC), forced expiratory volume in 1 s (FEV1), FEV1/FVC ratio, maximum mid-expiratory flow (MMEF), and forced expiratory flow at 25%, 50%, and 75% of FVC (FEF25, FEF50, FEF75). Bronchodilator responsiveness was evaluated after salbutamol inhalation by measuring changes in FEV1 and FVC, including absolute and percentage increases. Fractional exhaled nitric oxide (FeNO) levels were measured using standardized procedures. Correlations between BMI, FeNO levels, and pulmonary function parameters were analyzed. Statistical analysis was performed using appropriate tests. A two-tailed P value < 0.05 was considered statistically significant. No significant differences were observed in baseline pulmonary function parameters, including FVC% predicted, FEV1% predicted, FEV1/FVC, MMEF, FEF25, FEF50, and FEF75, across BMI groups (all P > 0.05). A significant difference in FEV1/FVC was observed between boys and girls (P < 0.05). After bronchodilator testing, a significant difference was observed only in the absolute increase in FVC among BMI groups (P = 0.016), whereas no significant difference was found in FEV1 improvement. Fractional exhaled nitric oxide (FeNO) levels were positively correlated with the absolute increase in FVC (r = 0.165, P = 0.002). No significant differences were observed in baseline pulmonary function parameters across BMI groups in children aged 4-14 years. However, differences in bronchodilator-induced changes in FVC were identified among different BMI categories, and FeNO levels were positively associated with bronchodilator-induced changes in FVC. These findings indicate that body mass index and FeNO are independently associated with bronchodilator-related changes in lung function in this population, which may be relevant when interpreting pediatric pulmonary function test results.

PMID 42602167
阅读全文 →

注册免费账户还可查看另外 9009 篇文献

免费注册查看全部文献 →

了解更多salbutamol